Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.
about
The 'invisible hand': regulation of RHO GTPases by RHOGDIsThe molecular effect of metastasis suppressors on Src signaling and tumorigenesis: new therapeutic targetsTargeting Cdc42 in cancerMetastasis suppressor genes at the interface between the environment and tumor cell growthRhoC Is an Unexpected Target of RhoGDI2 in Prevention of Lung Colonization of Bladder Cancer.PKCα phosphorylation of RhoGDI2 at Ser31 disrupts interactions with Rac1 and decreases GDI activity.The faces and friends of RhoGDI2.RhoGDI2 promotes epithelial-mesenchymal transition via induction of Snail in gastric cancer cells.Placenta-specific novel splice variants of Rho GDP dissociation inhibitor β are highly expressed in cancerous cells.Metastasis suppressors and the tumor microenvironmentSEPTIN2 and STATHMIN Regulate CD99-Mediated Cellular Differentiation in Hodgkin's Lymphoma.Rictor encounters RhoGDI2: the second pilot is taking a lead.Silencing of D4-GDI inhibits growth and invasive behavior in MDA-MB-231 cells by activation of Rac-dependent p38 and JNK signalingLentivirus vector-mediated Rho guanine nucleotide dissociation inhibitor 2 induces beta-2 adrenergic receptor desensitization in β2AR desensitization mice model.RhoGDI2 as a therapeutic target in cancer.Prognostic value of Rho GDP dissociation inhibitors in patients with hepatocellular carcinoma following liver transplantationRNA interference-mediated knockdown of RhoGDI2 induces the migration and invasion of human lung cancer A549 cells via activating the PI3K/Akt pathway.Overexpression of RhoGDI2 correlates with tumor progression and poor prognosis in colorectal carcinoma.
P2860
Q24606819-0C20EAFB-BDCC-49BC-B9DE-951DAAA088CBQ26782593-572AE470-BC38-405B-BF6B-6518D02E9440Q27028075-85831EDC-2E9F-449D-936A-4024E045D17DQ28394526-BBF0022C-264F-4CC8-8EAB-87E4AFDE0A37Q30301104-B4909B39-8A21-4FC2-B2FD-E3D88568E631Q30417613-4C529283-B1DE-4DE6-A7C4-3846B4D1534CQ30455699-75DB5B05-2399-4D09-8BF2-EEFDA25D5181Q33688924-C41310CC-725A-4C55-8A8A-D5838BA1A09CQ34498722-CFE78B9D-1652-4488-9A70-6599BEDFFDEEQ34648929-AAB7DB2C-1407-4A67-9FA4-D70722A4A9A7Q35639424-0315871C-977E-478D-8A5D-1E00E0374DCEQ37104803-85C6D676-EFF4-460A-BBC5-3A3C7233981DQ37176427-3A8F8D94-789F-48BC-BA64-880F6773BC51Q37620533-975D3AC5-2EAC-49F0-AB99-F353EC06E5A4Q37650185-055611F4-84C3-4B81-8B7C-867530803B7FQ38695493-A4983682-4270-4625-8203-6C3BD65C4A60Q38952177-E62B659C-9E79-4740-83E7-C098C1F3AE39Q39485959-192F9D15-DEFE-47B4-B28E-41E6AEEE3C83
P2860
Loss of expression of LyGDI (ARHGDIB), a rho GDP-dissociation inhibitor, in Hodgkin lymphoma.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
2007年學術文章
@zh
2007年學術文章
@zh-hant
name
Loss of expression of LyGDI (A ...... nhibitor, in Hodgkin lymphoma.
@en
type
label
Loss of expression of LyGDI (A ...... nhibitor, in Hodgkin lymphoma.
@en
prefLabel
Loss of expression of LyGDI (A ...... nhibitor, in Hodgkin lymphoma.
@en
P2093
P2860
P1476
Loss of expression of LyGDI (A ...... nhibitor, in Hodgkin lymphoma.
@en
P2093
Anna Sotnikova
Gaixiang Xu
Kristina Krause
Maciej Giefing
Matthias Krams
Wolfram Klapper
P2860
P304
P356
10.1111/J.1365-2141.2007.06782.X
P407
P577
2007-10-01T00:00:00Z